… cells that form the BBB limits the ability of many lipophilic compounds, including potential
therapeutic agents, to reach target sites in the CNS (for review, see Graff and Pollack 1 ). Due …

… tolerance development, which included consideration of the relationship between the
development of opioid tolerance and administration strategy, was utilized by Ouellet and Pollack (…

… Chen C, Pollack GM. Altered disposition and antinociception of [D-penicillamine(2,5)]enkephalin …
Chen C, Pollack GM. Extensive biliary excretion of the model opioid peptide [D-PEN2,5] …

The P-glycoprotein (P-gp)-deficient mouse model is used to assess the influence of P-gp-mediated
efflux on the central nervous system (CNS) distribution of drugs. The steady-state …

The efflux transporter P-glycoprotein (P-gp) is an important component of the blood–brain
barrier (BBB) that limits accumulation of many compounds in brain. Some opioids have been …

The ATP-driven drug export pump, P-glycoprotein, is a primary gatekeeper of the blood-brain
barrier and a major impediment to central nervous system (CNS) pharmacotherapy. …

This paper reviews trends in higher education, characterizing both the current learning
environments in pharmacy education as well as a vision for future learning environments, and …

An in situ mouse brain perfusion model predictive of passive and carrier-mediated transport
across the blood-brain barrier (BBB) was developed and applied to mdr1a P-glycoprotein (…

Hepatic disposition of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) and its diacetate
promoiety (CDFDA) was studied in isolated perfused rat livers. Livers from Wistar wild-type …

This study was conducted to assess the utility of unbound brain EC 50 (EC 50,u ) as a measure
of in vivo potency for centrally active drugs. Seven μ-opioid agonists (alfentanil, fentanyl, …